Drug Information

Drug General Information
Drug ID
D0X9UA
Former ID
DIB013670
Drug Name
Vatelizumab
Drug Type
Antibody
Indication Multiple scierosis [ICD9: 340; ICD10:G35] Phase 2 [524887]
Company
Pharmaceuticals
Target and Pathway
Target(s) Integrin alpha-2/beta-1 Target Info [544483]
Reactome Elastic fibre formation
Fibronectin matrix formation
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Cell surface interactions at the vascular wall
Basigin interactions
Molecules associated with elastic fibres
Integrin cell surface interactions
Laminin interactions
Syndecan interactions
ECM proteoglycans
Other semaphorin interactions
Localization of the PINCH-ILK-PARVIN complex to focal adhesions
CHL1 interactions
RHO GTPases Activate Formins
Platelet Adhesion to exposed collagen
WikiPathways TGF beta Signaling Pathway
Focal Adhesion
Human Complement System
Extracellular matrix organization
Interleukin-11 Signaling Pathway
Arrhythmogenic Right Ventricular Cardiomyopathy
miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
Platelet Adhesion to exposed collagen
Integrin-mediated Cell Adhesion
L1CAM interactions
Integrin cell surface interactions
References
Ref 524887ClinicalTrials.gov (NCT02222948) Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis. U.S. National Institutes of Health.
Ref 544483Sulfonamide inhibitors of alpha2beta1 integrin reveal the essential role of collagen receptors in in vivo models of inflammation. Pharmacol Res Perspect. 2015 June; 3(3): e00146.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.